ENPP1 Fluorescent Inhibitor Scre

Confirm delete?

ENPP1 Fluorescent Inhibitor Screening Assay Kit

Zoom

Cat No: 702090

Assay Kits - More Assay Kits

Cayman’s ENPP1 Inhibitor Screening Assay Kit provides a robust and easy-to-use platform for identifying novel inhibitors of human ENPP1, an ectonucleotide pyrophosphatase and phosphodiesterase implicated in multiple biological pathways, including the ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

ENPP 1

Product Overview:
Cayman’s ENPP1 Inhibitor Screening Assay Kit provides a robust and easy-to-use platform for identifying novel inhibitors of human ENPP1, an ectonucleotide pyrophosphatase and phosphodiesterase implicated in multiple biological pathways, including the cGAS/STING pathway, and bone mineralization. The assay uses an ENPP1-specific fluorogenic substrate, Tokyo Green™-mAMP (TG-mAMP). ENPP1 cleaves this substrate generating free Tokyo Green™, which can be easily quantified using a fluorescence plate reader at excitation and emission wavelengths of 485 and 520 nm, respectively. The potent and reversible ENPP1 inhibitor ENPP1 Inhibitor C Assay Reagent is included as a positive control.

Size	384 wells
Shipping	dry ice
Custom Code	3822.19
UNSPSC code	41116104

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.